To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy
NCT ID: NCT01842100
Last Updated: 2013-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2193 participants
INTERVENTIONAL
1999-09-30
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Feasibility of Simplified Telephone Follow-up After Medical Abortion
NCT00619658
Effects of Prior Induced Termination of Pregnancy on Complications and Pregnancy Outcomes.
NCT04183829
A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions
NCT02756403
Prolonged Treatment for Infected Abortion After Hospital Discharge.
NCT00376493
IUD Insertion Post First Trimester Abortion
NCT01174225
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Universal antibiotic prophylaxis
In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.
Universal antibiotic prophylaxis
100 mg twice daily for 7 days starting on the day of induced abortion
Screen-and-treat
In the screen-and-treat group, the results of screening for sexually transmitted infections (STI) were revealed to the patients. They would only receive appropriate specific antibiotics treatment only if they were screened positive for any of the STIs. If they were found to have STI, their sexual partners would also be referred to the local social hygiene clinics for contact tracing and treatment. Contraception by barrier methods would also be advised.
Screen-and-treat
Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Universal antibiotic prophylaxis
100 mg twice daily for 7 days starting on the day of induced abortion
Screen-and-treat
Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sofie SF Yung, MBBS, MRCOG
Role: PRINCIPAL_INVESTIGATOR
The University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queen Mary Hospital
Hong Kong, Hong Kong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QMHRC99 - 15 RC/B/121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.